Development and validation of a high-throughput assay for quantification of the proliferation inhibitor ABT-578 using LC/LC-MS/MS in blood and tissue samples

Therapeutic Drug Monitoring

Volumn 27, Issue 6, 2005, Pages 770-778

  Zhang, Yan Ling ^a   Bendrick Peart, Jamie ^a   Strom, Tobin ^a   Haschke, Manuel ^a   Christians, Uwe ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Automated sample preparation; Column switching; Drug eluting stents; LC MS; Sirolimus derivatives; Tissue concentrations

Indexed keywords

ABT 578; DRUG DERIVATIVE; GROWTH INHIBITOR; RAPAMYCIN;

ANIMAL TISSUE; BLOOD SAMPLING; CONFERENCE PAPER; CONTROLLED STUDY; DRUG SCREENING; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; HUMAN; LIQUID CHROMATOGRAPHY; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RABBIT; TANDEM MASS SPECTROMETRY; ANIMAL; ARTICLE; BLOOD; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; ELECTROSPRAY MASS SPECTROMETRY; METHODOLOGY; PHARMACEUTICS; REPRODUCIBILITY; TISSUE DISTRIBUTION;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GROWTH INHIBITORS; HUMANS; MOLECULAR STRUCTURE; RABBITS; REPRODUCIBILITY OF RESULTS; SIROLIMUS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TECHNOLOGY, PHARMACEUTICAL; TISSUE DISTRIBUTION;

EID: 33646829641     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000185766.52126.bd     Document Type: Conference Paper

References (28)

1. Nashan B. Review of the proliferation inhibitor everolimus. Expert Opin Investig Drugs. 2002;11:1845-1857.
2. Kahan BD. Sirolimus: a comprehensive review. Expert Opin Pharmacother. 2001;2:1903-1917.
3. Gregory CR, Huie P, Billingham ME, et al. Rapamycin inhibits arterial intima thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factors and cytokine response in injured vessels. Transplantation. 1993;55:1409-1418.
4. Hiatt BL, Carter AJ, Yeung AC. The drug-eluting stent. Is it the Holy Grail? Rev Cardiovasc Med. 2001;2:190-196.
5. Fattori R, Piva T. Drug-eluting stents in vascular intervention. Lancet. 2003;361:247-249.
6. Houghton PJ, Huang S. mTOR as target for cancer therapy. Curr Top Microbiol Immunol. 2004;274:339-359.
7. Morice MC, Serruys PW, Sousa JE, for the RAVEL study group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780.
8. Abizaid A, Costa M, Blannchard D, et al. Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients. Insights from the RAVEL trial. Eur Heart J. 2004;25:107-112.
9. 13C assignments for rapamycin. Magn Reson Chem. 2005;43:174-175.
10. Buellesfeld L, Grube E. ABT-578-eluting stents. The promising successor of sirolimus- and paclitaxel-eluting stent concepts? Herz. 2004;29:167-170.
11. Rogers CD. Optimal stent design for drug delivery. Rev Cardiovasc Med. 2004;4(Suppl. 2):S9-S15.
12. Ji QC, Reimer TM, El-Shourbagy TA. 96-Well liquid-liquid extraction liquid chromatography-tandem mass spectrometry method for the quantitative determination of ABT-578 in human blood samples. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;805:67-75.
13. Ji QC, Zhang J, Rodila R, et al. Method development for the quantitation of ABT-578 in rabbit artery tissue by 96-well liquid-liquid extraction and liquid chromatography/tandem mass spectrometry detection. Rapid Commun Mass Spectrom. 2004;18:2293-2298.
14. Streit F, Christians U, Schiebel HM, et al. Structural identification of four metabolites of the macrolide immunosuppressant sirolimus after in vitro metabolism by electrospray-MS/MS. Drug Metab Dispos. 1996;24:1272-1278.
15. Hallensleben K, Raida M, Habermehl G. Identification of a new metabolite of macrolide immunosuppressants, like rapamycin and SDZ-RAD, using high-performance liquid chromatography and electrospray tandem mass spectrometry. J Am Soc Mass Spectrom. 2000;11:516-525.
16. Müller C, Schäfer P, Störtzel M, et al. Ion suppression effects in liquid chromatrography-electrospray-ionization transport-region collision induced dissociation mass spectrometry with different serum extraction methods for systematic toxicological analysis with mass spectra libraries. J Chromatogr B. 2002;773:47-52.
17. Streit F, Armstrong VW, Oellerich M. Mass interferences in quantification of cyclosporine using tandem mass spectrometry without chromatography. Ther Drug Monit. 2003;25:506.
18. Huber R, Zech K. Determination of drugs and their metabolites in biological samples by fully automated HPLC with on-line extraction and pre-column switching. In: Frei RW, Zech K, eds. Selective Sample Handling and Detection in High-Performance Liquid Chromatography. Journal of Chromatography Library, vol 39A. Amsterdam: Elsevier; 1988, pp 81-144.
19. Christians U, Jacobsen W, Serkova N, et al. Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: immunosuppressants. J Chromatogr B. 2000;748:41-53.
20. Streit F, Armstrong VW, Oellerich M. Rapid liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus, and cyclosporine in whole blood. Clin Chem. 2002;48:955-958.
21. Vidal C, Kirchner GI, Wuensch G, et al. Automated simultaneous quantification of the immunosuppressant 40-O-(2-hydroxyethyl) rapamycin and cyclosporine in blood with electrospray-mass spectrometric detection. Clin Chem. 1998;44:1275-1282.
22. Kirchner GI, Vidal C, Jacobsen W, et al. Simultaneous on-line extraction and analysis of sirolimus (rapamycin) and ciclosporin in blood by liquid chromatography-electrospray mass spectrometry. J Chromatogr B. 1999;721:285-294.
23. Kirchner GI, Vidal C, Winkler M, et al. LC/ESI-MS allows simultaneous and specific quantification of SDZ-RAD and cyclosporine, including groups of their metabolites in human blood. Ther Drug Monit. 1999;21:116-122.
24. Deters M, Resch K, Kaever V. Simultaneous quantification of sirolimus, everolimus, tacrolimus and cyclosporine by liquid chromatography-mass spectrometry (LC-MS). Clin Chem Lab Med. 2002;40:285-292.
25. Kovarik JM, Kaplan B, Tedesco Silva H, et al. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation. 2002;73:920-925.
26. Yatscoff RW, Boeckx R, Holt DW, et al. Consensus guidelines for therapeutic drug monitoring of rapamycin: report of the consensus panel. Ther Drug Monit. 1996;29:43-49.
27. Serkova N, Hausen B, Berry GJ, et al. Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: interaction with cyclosporine. J Pharmacol Exp Ther. 2000;294:323-332.
28. Wang PC. Chan KW, Schiksnis RA, Scatina J, Sisenwine SF. High-performance liquid chromatographic isolation, spectroscopic characterization, and immunosuppressive activities of two rapamycin degradation products. J Liq Chromatogr. 1994;17:3383-3392.